FDA Investigator Brochure Guidance: Contents, Updates, Distribution

The FDA’s requirements for an Investigator’s Brochure sit in 21 CFR 312.23(a)(5): the brochure must describe the investigational drug’s substance and formulation, summarize its pharmacological and toxicological effects in animals and humans, explain its pharmacokinetics, present safety and effectiveness data from any prior human studies, and set out anticipated risks and precautions.¹ Those five categories are the legal floor. The sponsor’s harder job is keeping the brochure accurate as the trial generates new information, because the IB is what the FDA uses to judge whether adverse events are expected, whether investigators are properly informed, and whether the study should be allowed to continue.

What Must Be in the Brochure

The five content areas required by 21 CFR 312.23(a)(5) are:

A description of the drug substance and formulation, including the structural formula if known.
A summary of the drug’s pharmacological and toxicological effects in animals and, where available, in humans.
Pharmacokinetic information covering absorption, distribution, metabolism, and elimination in animals and, if known, in humans.
Safety and effectiveness results from any prior human studies, with published reprints appended when useful.
Anticipated side effects based on prior experience with the drug or related compounds, along with any special monitoring the investigator should perform.

These items are the minimum. Most brochures go further, because the international Good Clinical Practice guideline the FDA has adopted expects a fuller structure.

The ICH E6(R3) Structure Reviewers Expect

The FDA finalized its adoption of the ICH E6(R3) Good Clinical Practice guideline in September 2025.² Appendix A of that guideline lays out the section-by-section framework sponsors and regulators worldwide now expect to see in an IB:

Table of contents.
Summary — a concise overview, ideally no more than two pages, of the most significant chemical, pharmacological, toxicological, and clinical information.
Introduction — chemical and trade names, pharmacological class, rationale for the research, and the anticipated indication.
Physical, chemical, and pharmaceutical properties, including the formulation, excipients, and storage and handling instructions.
Nonclinical studies, organized by pharmacology, pharmacokinetics, and toxicology, with toxicology broken down by single-dose, repeated-dose, genotoxicity, carcinogenicity, reproductive toxicity, and local tolerance.
Effects in humans, covering pharmacokinetics, safety and efficacy from completed and ongoing trials, and any marketed-use experience.
Summary of data and guidance for the investigator, tying the nonclinical and clinical evidence together and giving practical direction on managing risks.

The guideline calls for literature references at the end of each chapter where appropriate.³ FDA’s own guidance document on IBs adds that the summary for the investigator should specifically address known and potential risks, benefits, contraindications, toxicities, drug-drug interactions, drug-food interactions, drug-laboratory test interactions, and drug-disease interactions.⁴ A sponsor that follows the E6(R3) structure will satisfy 21 CFR 312.23 and meet the expectations of IRBs and non-US regulators at the same time.

When an IB Is and Isn’t Required

The obligation to prepare and distribute an IB comes from 21 CFR 312.55, which applies to sponsors other than sponsor-investigators.⁵ Section 312.23(a)(5) reinforces the point by requiring the IB in the IND submission only “if required under § 312.55.”¹ A sponsor-investigator, meaning someone who both initiates and personally conducts the study, is not required to produce a standalone brochure to hand to themselves. The underlying pharmacology, toxicology, and prior human experience data still have to appear elsewhere in the IND; only the packaging obligation is lifted.

The picture shifts again for marketed drugs. An IND is still required when the goal is to support a new indication with a well-controlled study.⁶ The approved package insert often substitutes for a full IB because it already contains the drug’s pharmacology, toxicology, clinical data, and safety profile. Off-label prescribing that happens in ordinary clinical practice, outside a formal investigation, is exempt from Part 312 entirely and needs no IND or IB.

How the IB Controls Adverse-Event Classification

The IB is not just a reference document. Under 21 CFR 312.32, an adverse event counts as “unexpected” if it is not listed in the IB, or if it is not listed at the severity or specificity actually observed.⁷ The regulation offers a clean example: if the IB lists only elevated liver enzymes, hepatic necrosis is unexpected because of its greater severity; if the IB references cerebral vascular accidents generally, cerebral thromboembolism is unexpected because of its greater specificity. Events noted as occurring with the drug class but not with the specific investigational drug are also unexpected.

That classification triggers expedited reporting: 15 calendar days for unexpected serious adverse reactions suggesting a significant risk, and 7 calendar days for reactions that are fatal or life-threatening.⁷ A brochure that understates known risks generates expedited reports that shouldn’t have been necessary; one that overstates the profile hides genuinely new signals inside a longer “expected” list. Accuracy in the safety sections is where the document does its regulatory work.

Keeping the IB Current

An IB has to be reviewed at least once a year and revised whenever significant new information affects participant safety or the conduct of the trial. Section 312.32 states that findings from epidemiological studies, pooled analyses, clinical trials, or animal and in vitro testing that suggest a significant human risk “would ordinarily result in a safety-related change in the protocol, informed consent, investigator brochure, or other aspects of the overall conduct of the clinical investigation.”⁷ The “ordinarily would” language treats the update as the default; a sponsor that receives such findings and does not revise the IB needs a defensible reason.

The reporting clock for the underlying safety information is short: 15 calendar days for significant-risk findings, 7 calendar days for unexpected fatal or life-threatening reactions, running from the sponsor’s initial receipt of the information. A full IB revision can follow on a longer timeline, but the initial written notice to investigators cannot wait for a new brochure to be printed.

Revised brochures also have to reach the FDA. If the revision is close in time to an annual report, it can be included there, since annual reports must describe any IB revision and attach the new version. Otherwise, the sponsor submits the revision through an information amendment, the catch-all mechanism for important IND updates that fall outside a protocol amendment or safety report.⁶

Distributing the IB and Its Updates

Before any participant is enrolled, the sponsor must provide the current IB to every participating clinical investigator.⁵ Content must be truthful and balanced. There is no requirement that the data be favorable, only that they be complete and accurate.

As the study progresses, the sponsor has to keep every investigator informed of new observations, particularly about adverse effects and safe use. Section 312.55 permits several methods: periodically revised IBs, reprints of published studies, letters to investigators, or other appropriate means. For important safety information, though, the expedited reporting requirements of 312.32 govern, and a routine letter is not enough. Investigators, in turn, are expected to route updated safety information to their IRB so the board can decide whether informed consent needs to be revised.

Record Retention

Sponsors have to retain all records and reports required under Part 312, including every version of the IB, for two years after a marketing application is approved for the drug. If no marketing application is ever approved, the period runs until two years after shipment of the investigational drug is discontinued and the FDA has been notified.⁸ Many sponsors hold IB records well beyond the minimum because the data may be needed for post-marketing safety work or litigation years later.

What Happens If the IB Falls Short

An inadequate IB can stop a clinical program. Under 21 CFR 312.42, the FDA may place a proposed or ongoing clinical investigation on hold if the brochure is “misleading, erroneous, or materially incomplete.”⁹ This ground applies across Phase 1, Phase 2, Phase 3, and studies not designed to be adequate and well-controlled. A clinical hold halts new enrollment, may halt dosing of already-enrolled participants, and stays in place until the sponsor resolves the deficiency to the FDA’s satisfaction.

Bioresearch monitoring inspections also produce Form 483 observations when sponsors miss IB obligations. Common findings include failure to distribute updated safety information to investigators under 312.55 and failure to submit annual reports that should include revised brochures.¹⁰ Those observations can escalate to warning letters, which are public and can damage a sponsor’s standing with investigators, IRBs, and prospective partners. Treating the IB as a living document, reviewed on schedule and revised whenever new safety data warrants, is the most reliable way to keep a program moving.